Pantazis N, Psichogiou M, Paparizos V, Gargalianos P, Chini M, Protopapas K, Sipsas NV, Panos G, Chrysos G, Sambatakou H, et al. Treatment Modifications and Treatment-Limiting Toxicities or Side Effects: Risk Factors and Temporal Trends. AIDS research and human retroviruses. 2015;31:707–717.

Boosted lopinavir–versus boosted atazanavir–containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. Clinical Infectious Diseases. 2015;60:1262–1268.

Simmons R, Malyuta R, Chentsova N, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K, in EuroCoord CASCADEC, others. HIV testing and diagnosis rates in Kiev, Ukraine: April 2013-March 2014. PloS one. 2015;10:e0137062.

Jarrin I, Pantazis N, Dalmau J, Phillips AN, Olson A, Mussini C, Boufassa F, Costagliola D, Porter K, Blanco J, et al. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. AIDS (London, England). 2015;29:2323.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miro JM, Ferrer E, et al. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. The lancet HIV. 2015;2:e335–e343.